Seeking Alpha
01 Jul 2026, 03:09 UTC · 3h ago
AtaiBeckley: BPL-003's Promising Potential On TRD Keeps Me Bullish
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
Seeking Alpha
01 Jul 2026, 03:09 UTC · 3h ago
NewsImpactScreener rates every claim in this story for market impact and maps it to the tickers most exposed.
What the story claims
3 claims · each scored for market impact
BPL-003 will proceed to a two-study Phase 3 trial for Treatment-Resistant Depression (TRD) following FDA alignment. — Progression to Phase 3 is a major regulatory milestone for a lead asset targeting a large market, though the 2029 timeline is distant.
+0.60VLS-01 provides a near-term catalyst for TRD in Q4 2026. — A shorter-term clinical catalyst provides a more immediate driver for stock price volatility compared to the 2029 readout.
+0.40EMP-01 is being developed to provide optionality in treating social anxiety disorders. — Secondary indications provide diversification and additional value, but carry less weight than lead TRD assets.
+0.20Which stocks this story touches
Continue reading
6 related stories
Search tags
The company has a focused pipeline with a clear path to Phase 3 trials and multiple upcoming clinical catalysts.
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
How the impact breaks down
Where the story's weight lands
Stocks most exposed
Modeled from each name's sensitivity to this story
No stock impact ranking available yet.
CNBC
23h ago
